Aptevo Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

APVO$1.13-8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts, unaudited)

	June 30, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$8,066	$16,904
Prepaid expenses	798	1,473
Other current assets	715	689
Total current assets	9,579	19,066
Property and equipment, net	697	895
Operating lease right-of-use asset	4,645	4,881
Total assets	$14,921	$24,842
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities	$3,736	$3,984
Accrued compensation	892	2,098
Other current liabilities	791	1,142
Total current liabilities	5,419	7,224
Other long-term liabilities	14	—
Operating lease liability	5,025	5,397
Total liabilities	10,458	12,621
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding	—	—
Common stock: $0.001 par value; 500,000,000 shares authorized; 4,080,665 and 442,458 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	69	61
Additional paid-in capital	240,558	235,607
Accumulated deficit	(236,164)	(223,447)
Total stockholders' equity	4,463	12,221
Total liabilities and stockholders' equity	$14,921	$24,842

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.